Butbul Aviel Yonatan, Hashkes Philip J, Dizitzer Yotam, Inbar Kanteman, Berkun Yackov, Eisenstein Eli M, Hamad Saied Mohamad, Goldzweig Ofra, Heshin-Bekenstein Merav, Ling Eduard, Feldon Michal, Tal Rotem, Pinchevski-Kadir Shiran, Tirosh Irit, Harel Liora, Amarilyo Gil, Kaidar Kfir
Department of Pediatrics and Pediatric Rheumatology Service, Rambam Health Care Campus, Ruth Children's Hospital, Haifa 2611001, Israel.
Pediatric Rheumatology Unit, Shaare Zedek Medical Center, Hebrew University-Hadassah School of Medicine, Jerusalem 9103401, Israel.
Vaccines (Basel). 2022 Jul 29;10(8):1207. doi: 10.3390/vaccines10081207.
Since the development of COVID-19 vaccines, more than 4.8 billion people have been immunized worldwide. Soon after vaccinations were initiated, reports on cases of myocarditis following the second vaccine dose emerged. This study aimed to report our experience with adolescent and young adults who developed post-COVID-19 vaccine myocarditis and to compare these patients to a cohort of patients who acquired pediatric inflammatory multisystem syndrome (PIMS/PIMS-TS) post-COVID-19 infection.
We collected reported cases of patients who developed myocarditis following COVID-19 vaccination (Pfizer mRNA BNT162b2) from all pediatric rheumatology centers in Israel and compared them to a cohort of patients with PIMS.
Nine patients with post-vaccination myocarditis were identified and compared to 78 patients diagnosed with PIMS. All patients with post-vaccination myocarditis were males who developed symptoms following their second dose of the vaccine. Patients with post-vaccination myocarditis had a shorter duration of stay in the hospital (mean 4.4 ± 1.9 vs. 8.7 ± 4.7 days) and less myocardial dysfunction (11.1% vs. 61.5%), and all had excellent outcomes as compared to the chronic changes among 9.2% of the patients with PIMS.
The clinical course of vaccine-associated myocarditis appears favorable, with resolution of the symptoms in all the patients in our cohort.
自新冠病毒疫苗研发以来，全球已有超过48亿人接种了疫苗。疫苗接种开始后不久，就出现了关于第二剂疫苗接种后心肌炎病例的报告。本研究旨在报告我们对接种新冠病毒疫苗后发生心肌炎的青少年和年轻人的经验，并将这些患者与一组新冠病毒感染后患上儿童炎症性多系统综合征（PIMS/PIMS-TS）的患者进行比较。
我们收集了以色列所有儿科风湿病中心报告的接种新冠病毒疫苗（辉瑞mRNA BNT162b2）后发生心肌炎的患者病例，并将他们与一组PIMS患者进行比较。
确定了9例接种疫苗后发生心肌炎的患者，并与78例被诊断为PIMS的患者进行比较。所有接种疫苗后发生心肌炎的患者均为男性，在接种第二剂疫苗后出现症状。接种疫苗后发生心肌炎的患者住院时间较短（平均4.4±1.9天对8.7±4.7天），心肌功能障碍较少（11.1%对61.5%），与9.2%的PIMS患者出现的慢性变化相比，所有患者预后良好。
疫苗相关心肌炎的临床病程似乎较好，我们队列中的所有患者症状均得到缓解。
